Researchers from Free University Provide Details of New Studies and Findings in the Area of Drug Delivery Systems (Rhamnolipids form drug-loaded nanoparticles for dermal drug delivery)
By a News Reporter-Staff News Editor at Nanotechnology Weekly Current study results on Drugs and Therapies - Drug Delivery Systems have been published. According to news originating from Berlin, Germany, by VerticalNews correspondents, research stated, "Bacterial biosurfactants are nature's strategy to solubilize and ingest hydrophobic molecules and nutrients using a fully biodegradable transport system. Eight structurally defined rhamnolipids were selected and investigated as potential drug carrier systems."
Our news journalists obtained a quote from the research from Free University, "Depending on the molecular structures defining their packing parameters, the rhamnolipids were found to form spherical nanoparticles with precisely defined average sizes between 5 and 100 nm, low polydispersity, and stability over a broad concentration range as revealed from dynamic light scattering and electron microscopy. As rhamnolipids were tolerated well by the human skin, rhamnolipid nanoparticles were considered for dermal drug delivery and thus loaded with hydrophobic drug molecules. Using the drug model, Nile red, dexamethasone, and tacrolimus nanoparticles charged with up to 30% drug loading (w/w) were obtained. Nanoparticles loaded with Nile red were investigated for dermal drug delivery in a Franz cell using human skin. Fluoresence microscopy of skin slices indicated the efficient penetration of the model drug into human skin, both into the stratum corneum and although to a lesser extent into the lower epidermis."
According to the news editors, the research concluded: "Rhamnolipid nanocarriers were found to be non-toxic to primary human fibroblasts in a proliferation assay and thus are considered candidates for the dermal delivery of drugs."
For more information on this research see: Rhamnolipids form drug-loaded nanoparticles for dermal drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2017;116():31-37. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.journals.elsevier.com/european-journal-of-pharmaceutics-and-biopharmaceutics/)
The news correspondents report that additional information may be obtained from J. Rademann, Free University of Berlin, Inst Pharm, Medical Chem, D-14195 Berlin, Germany. Additional authors for this research include S. Honzke, W.O. Luthardt, E.L. Wong, M. Unbehauen, J. Bauer, R. Haag, S. Hedtrich, E. Ruhl and F. Muller.
Keywords for this news article include: Berlin, Germany, Europe, Drug Delivery Systems, Emerging Technologies, Drugs and Therapies, Nanotechnology, Nanoparticle, Free University.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC